Feyhan ÖKTEN, Menekşe HASDOĞAN, Ayşegül TARHAN

Bupivakain kardiyotoksisitesi ne derece önemlidir?

Bupivakain uzun etki süresi ve kaliteli anestezi ve analjezi yaratması nedeniyle anestezi pratiğinde yaygın olarak kabul görmüştür ve günümüzde halen yaygın olarak kullanılmaktadır. Ancak ilk kez 1979 yılında olmak üzere geçmişten bugüne kadar çok sayıda bupivakaine bağlı toksisite olguları bildirilmiştir. Anestezinin her alanında olduğu gibi rejyonal anestezideki gelişmelere parelel olarak lokal anestezikler için de ideal ajanı bulma çabaları devam etmektedir. Biliyoruz ki ideal lokal anestezik ajanın özellikleri arasında yanlış uygulamalar sonucu ortaya çıkan yan etkilerin en aza indirilmiş olması şarttır. Bu derlemede halen kullanmakta olduğumuz lokal anesteziklerin toksisite açısından artılarının ve eksilerinin değerlendirilmesi amaçlanmıştır.

What is the importance of bupivacaine cardiotoxicity

Bupivacaine is a well known and widely used local anesthetic due to its long acting effect, and high quality of anesthesia and analgesia. However, since 1979 a great number of bupivacaine toxicity cases have been reported. The efforts to find the ideal local anesthetics are ongoing to progres paralel with developments in the regional anesthesia likewise in all fields of anesthesia. It is well known that a low side effect incidence during incorrect administrations of local anesthetics is mandatory for a ideal local anesthetic. The aim of this review was to evaluate the positive and negative aspects of local anesthetics regarding to the toxicity.

PDF

___

1. Leone S, Di Cianni, Casati A, Fanelli G. Pharmacology, toxicology, and clinical use of new long acting local anesthetics, ropivacaine and levobupivacaine. Acta Biomed 2008; 79: 92-105.
2. Udelsmann A, Sa Lorena SER, Girioli SU, et al. Hemodynamic effects of local anesthetics intoxication. Experimental study in swine with levobupivacaine and bupivacaine. Acta Cirurgica Brasileira 2008; 23: 55-64.
3. Stewart J, Kellett N, Castro D. The central nervous system and cardiovascular effects of levobupivacaine and ropivacaine in healthy volunteers. Anesth Analg 2003; 97: 412-6.
4. Ekenstam BAF, Egner B, Petterson GN. N-alkyl pyrrolidine and N-alkyl piperidine carboxylic acid amines. Acta Chem Scand 1957; 11: 1183-90.
5. Albright GA. Cardiac arrest following regional anesthesia with etidocaine and bupivacaine. Anesthesiology 1979; 51: 285-7.
6. Davis NL, De Jong RH. Successful resuscitation following massive bupivacaine overdose. Anesth Analg 1982; 61: 62-4.
7. Royse Colin F, Royse Alistair G. The miocardial and vascular effects of bupivacaine, levobupivacaine, and ropivacaine using pressure volume loops. Anesth Analg 2005; 101: 679-87.
8. Ohmura S, Kawada M, Ohta T, et al. Systemic toxicity and resus-citation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats. Anesth Analg 2001; 93: 743-8.
9. Feldman HS, Arthur GR, Covino BG. Comparative systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine, bupivacaine and lidocaine in the conscious dog. Anesth Analg 1989; 69: 794-801.
10. Santos AC, Arthur GR, Wlody D, et al. Comparative systemic toxicity of ropivacaine and bupivacaine in nonpregnant and pregnant ewes. Anesthesiology 1995; 82: 734-40.
11. Dony P, Dewinde V, Vanderick B, et al. The comparative toxicity of ropivacaine and bupivacaine at equipotent doses in rats. Anesth Analg 2000; 91: 1489-92.
12. Valenzuela C, Snyders DJ, Bennett Pb, Tamargo J, Hondeghem LM. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Circulation 1995; 92: 3014-24.
13. Ecoffey C. Local anesthetics in pediatric anesthesia: an update. Minerva Anesthesiol 2005; 71: 357-60.
14. Krıkava I, Jarkovsky J, Stourac P, Novakova M, Sevcik P. The effects of lidocaine on bupivacaine-induced cardiotoxicity in the isolated rat heart. Physiol Res 2010; 59: S65-9.
15. Satsumae T, Tanaka M, Saito S, Inomata S. Convulsions after ropivacaine 300 mg for brachial plexus block. Br J Anaesth 2008; 101: 860-2.
16. Raeder JC, Drosdahl S, Klaastad O, et al. Axillary brachial plexus block with ropivacaine 7,5 mg/ml. A comparative study with bupivacaine 5 mg/ml. Acta Anaesthesiol Scand 1999; 43: 794-8.
17. Beilin Y, Halpern S. Ropivacaine versus bupivacaine for epidural labor analgesia. Anesth Analg 2010; 111: 482-7.
18. Moler R, Covino BG. Cardiac electrophysiologic properties of bupivacaine and lidocaine compared with those of ropivacaine, a new amide local anesthetic. Anesthesiology 1990; 72: 322-9.
19. Kindler CH, Yost CS. Two-pore domain potassium channels: new sites of local anesthetic action and toxicity. Reg Anesth Pain Med 2005; 30: 260-74.
20. Chang DH, Ladd LA, Copeland S, Iglesias MA, Plummer JL, Mather LE. Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep. Br J Pharmacol 2001; 132: 649-58.
21. Nancarrow C, Rutten AJ, Runciman WB, et al. Myocardial and cerebral drug concentrations and the mechanisms of death after fatal intravenous doses of lidocaine, bupivacaine, and ropivacaine in the sheep. Anesth Analg 1989; 69: 276-83.
22. Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563-9.
23. Marwick PC, Levin AI, Coetzee AR. Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest. Anesth Analg 2009; 108: 1344-6.